The randomized, multicenter open-label trial, presented at Digestive Disease Week, sought to determine whether treatment failure was less frequent with cyclosporine than with infliximab.
About 25 percent of patients with ulcerative colitis have acute severe ulcerative colitis. While intravenous corticosteroids are the primary therapy, 40 percent of patients are refractory to them, leaving cyclosporine or infliximab, as the only two medical options to avoid colectomy.
Read the Internal Medicine News report on ulcerative colitis.
Related Articles on Ulcerative Colitis:
Study: Social Support May Influence Colectomy Decision
Study: Patients Taking Isotretinoin at Increased Risk of Ulcerative Colitis
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
